Description
Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00)
A61P 3/00
Sub-Class
Stats
- 481 US PATENTS IN FORCE
- 142 US APPLICATIONS PENDING
- 143 Total Patent Owners
- 10,695 TOTAL INVENTORS
Recent Patents
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| 11980620 | Compounds and methods for treatment of Diamond Blackfan anemia | Jun 08, 17 | May 14, 24 | The Children's Medical Center Corporation |
| 11969408 | Method for improving mitophagy in subjects | Mar 08, 18 | Apr 30, 24 | AMAZENTIS SA |
| 11969457 | Application of skeletal muscle secreted factor THBS4 in preparation of drug for improving systemic glucose and lipid metabolism | Dec 06, 22 | Apr 30, 24 | Institute of Microbiology, Guangdong Academy of Sciences(Guangdong Detection Center of Microbiology) |
| 11963529 | Application of structurally altered gas molecules to enhance production of adenosine triphosphate in living organisms with no increase in reactive oxygen species | Oct 04, 23 | Apr 23, 24 | H2Plus LLC; H2Plus Operations, LLC; |
| 11957649 | Methods and pharmaceutical preparations for elevating ketone utilization | May 25, 21 | Apr 16, 24 | GLYKON TECHNOLOGIES GROUP, LLC |
| 11958833 | Compounds | Aug 16, 21 | Apr 16, 24 | MISSION THERAPEUTICS LIMITED |
| 11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) | Aug 11, 21 | Apr 16, 24 | Amgen Inc. |
| 11945786 | Compounds, devices, and uses thereof | Oct 03, 17 | Apr 02, 24 | SIGILON THERAPEUTICS, INC. |
| 11945853 | Genetically modified probiotics for oral delivery of renin-angiotensin related therapeutic proteins and peptides | Jun 14, 22 | Apr 02, 24 | University of Florida Research Foundation Incorporated |
| 11939300 | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 | Aug 20, 21 | Mar 26, 24 | ImmunoMolecular Therapeutics, Inc. |
| 11939601 | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria | Nov 21, 18 | Mar 26, 24 | ModernaTX, Inc. |
| 11932677 | Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases | Feb 28, 22 | Mar 19, 24 | AliveGen Inc. |
| 11932885 | Use of glutamine synthetase for treating hyperammonemia | Jun 03, 22 | Mar 19, 24 | Thoeris GmbH |
| 11925674 | Methods for regulating free fatty acid flux using fat specific protein 27 (FSP27) compositions | Jul 26, 22 | Mar 12, 24 | Ohio University |
| 11918633 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects | May 18, 22 | Mar 05, 24 | Biomarin Pharmaceutical Inc. |
| 11918687 | SDC-2 exosome compositions and methods of isolation and use | Jan 13, 17 | Mar 05, 24 | Orbsen Therapeutics Limited |
| 11912718 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | Aug 03, 21 | Feb 27, 24 | Gilead Apollo, LLC |
| 11903974 | Methods and compositions relating to chondrisomes from cultured cells | Nov 30, 16 | Feb 20, 24 | Flagship Pioneering Innovations V, Inc.; The Children's Medical Center Corporation; |
| 11903975 | Methods and compositions relating to chondrisomes from blood products | Nov 30, 16 | Feb 20, 24 | Flagship Pioneering Innovations V, Inc.; The Children's Medical Center Corporation; |
| 11903981 | in preventing and/or treating metabolic diseases | Dec 07, 18 | Feb 20, 24 | BGI SHENZHEN |
Recent Publications
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2024/0175,011 | GENE EDITING SYSTEM FOR EDITING THE ARYLSULFATASE A (ARSA) GENE | Nov 30, 22 | May 30, 24 | Not available |
| 2024/0175,050 | METHODS AND MATERIALS FOR TREATING PROPIONIC ACIDEMIA | Mar 18, 22 | May 30, 24 | Not available |
| 2024/0165,171 | COMPOSITION FOR ENHANCING PHYSIOLOGICAL EFFICACY OF LACTIC ACID BACTERIA | Mar 23, 22 | May 23, 24 | Not available |
| 2024/0166,662 | THIOPHENE BASED COMPOUNDS AND USE THEREOF AS BCKDK INHIBITORS | Feb 21, 22 | May 23, 24 | Not available |
| 2024/0156,913 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Oct 06, 23 | May 16, 24 | Singapore Health Services Pte Ltd.; National University of Singapore; |
| 2024/0156,987 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | Jun 02, 23 | May 16, 24 | Not available |
| 2024/0148,805 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Jan 16, 24 | May 09, 24 | Research Development Foundation |
| 2024/0148,866 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | Feb 11, 22 | May 09, 24 | DENALI THERAPEUTICS, INC. |
| 2024/0150,736 | FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF | Jan 12, 24 | May 09, 24 | DENALI THERAPEUTICS, INC. |
| 2024/0139,147 | METHOD FOR IMPROVING BIOAVAILABILITY OF NAD+ DERIVATIVES | Sep 15, 23 | May 02, 24 | Not available |
| 2024/0139,167 | LYSOSOME-ASSOCIATED MEMBRANE PROTEIN TARGETING COMPOUNDS AND USES THEREOF | Feb 16, 22 | May 02, 24 | Not available |
| 2024/0139,234 | PHARMACEUTICAL POLYMER FOR TREATING HYPERKALEMIA AND PREPARATION METHOD THEREOF | Nov 04, 21 | May 02, 24 | WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD. |
| 2024/0132,528 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | Aug 31, 23 | Apr 25, 24 | Not available |
| 2024/0132,535 | OXYSTEROLS AND METHODS OF USE THEREOF | Jun 29, 23 | Apr 25, 24 | Not available |
| 2024/0123,040 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | Feb 04, 22 | Apr 18, 24 | Not available |
| 2024/0115,558 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | Dec 23, 21 | Apr 11, 24 | Not available |
| 2024/0115,566 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | Dec 16, 21 | Apr 11, 24 | Not available |
| 2024/0115,630 | BIFIDOBACTERIA FOR REDUCING FOOD, ENERGY AND/OR FAT INTAKE | May 15, 23 | Apr 11, 24 | Not available |
| 2024/0115,661 | METHODS OF TREATING METABOLIC DISORDERS WITH FGF21 VARIANTS | Jul 26, 23 | Apr 11, 24 | Not available |
| 2024/0117,328 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) | Jan 31, 22 | Apr 11, 24 | Not available |
Top Owners in This Subclass
| Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
|---|
Patents Issued To Date - By Filing Year
Average Time to Issuance
- 32 Months (last 2 years Issuances)
- 32 Months (last 5 years Issuances)